OBJECTIVE: To investigate the direct effect of onabotulinumtoxinA (OnaBotA) on bladder afferent nerve activity and release of ATP and acetylcholine (ACh) from the urothelium. MATERIALS AND METHODS: Bladder afferent nerve activity was recorded using an in vitro mouse preparation enabling simultaneous recordings of afferent nerve firing and intravesical pressure during bladder distension. Intraluminal and extraluminal ATP, ACh, and nitric oxide (NO) release were measured using the luciferin-luciferase and Amplex(®) Red assays (Molecular Probes, Carlsbad, CA, USA), and fluorometric assay kit, respectively. OnaBotA (2U), was applied intraluminally, during bladder distension, and its effect was monitored for 2 h after application. Whole-nerve activity was analysed to classify the single afferent units responding to physiological (low-threshold [LT] afferent <15 mmHg) and supra-physiological (high-threshold [HT] afferent >15 mmHg) distension pressures. RESULTS: Bladder distension evoked reproducible pressure-dependent increases in afferent nerve firing. After exposure to OnaBotA, both LT and HT afferent units were significantly attenuated. OnaBotA also significantly inhibited ATP release from the urothelium and increased NO release. CONCLUSION: These data indicate that OnaBotA attenuates the bladder afferent nerves involved in micturition and bladder sensation, suggesting that OnaBotA may exert its clinical effects on urinary urgency and the other symptoms of overactive bladder syndrome through its marked effect on afferent nerves.
OBJECTIVE: To investigate the direct effect of onabotulinumtoxinA (OnaBotA) on bladder afferent nerve activity and release of ATP and acetylcholine (ACh) from the urothelium. MATERIALS AND METHODS: Bladder afferent nerve activity was recorded using an in vitro mouse preparation enabling simultaneous recordings of afferent nerve firing and intravesical pressure during bladder distension. Intraluminal and extraluminal ATP, ACh, and nitric oxide (NO) release were measured using the luciferin-luciferase and Amplex(®) Red assays (Molecular Probes, Carlsbad, CA, USA), and fluorometric assay kit, respectively. OnaBotA (2U), was applied intraluminally, during bladder distension, and its effect was monitored for 2 h after application. Whole-nerve activity was analysed to classify the single afferent units responding to physiological (low-threshold [LT] afferent <15 mmHg) and supra-physiological (high-threshold [HT] afferent >15 mmHg) distension pressures. RESULTS: Bladder distension evoked reproducible pressure-dependent increases in afferent nerve firing. After exposure to OnaBotA, both LT and HT afferent units were significantly attenuated. OnaBotA also significantly inhibited ATP release from the urothelium and increased NO release. CONCLUSION: These data indicate that OnaBotA attenuates the bladder afferent nerves involved in micturition and bladder sensation, suggesting that OnaBotA may exert its clinical effects on urinary urgency and the other symptoms of overactive bladder syndrome through its marked effect on afferent nerves.
Authors: Leonie Durnin; Benjamin Kwok; Priya Kukadia; Roisin McAvera; Robert D Corrigan; Sean M Ward; Ying Zhang; Qi Chen; Sang Don Koh; Kenton M Sanders; Violeta N Mutafova-Yambolieva Journal: J Physiol Date: 2018-11-02 Impact factor: 5.182
Authors: Leonie Durnin; Sebastien Hayoz; Robert D Corrigan; Andrew Yanez; Sang Don Koh; Violeta N Mutafova-Yambolieva Journal: Am J Physiol Renal Physiol Date: 2016-07-27
Authors: Kevin Krughoff; Faith L Anderson; Scott Palisoul; Alison L Young; Jason R Pettus; Karen L Moodie; Christopher Ogomo; Steven S Tau; Rachel A Moses; Matthew C Havrda; David R Chavez Journal: World J Urol Date: 2020-07-21 Impact factor: 4.226
Authors: Timothy J Searl; Danuta I Dynda; Shaheen R Alanee; Ahmed M El-Zawahry; Kevin T McVary; Eugene M Silinsky Journal: J Pharmacol Exp Ther Date: 2015-11-03 Impact factor: 4.030